WEE1 and acute myeloid leukemia: Among top-scoring hits, with the potential for clinical translation, histone deacetylase inhibitors (HDACis), proteasome modulators, topoisomerase and protein kinase inhibitors reduced the growth of EVI1High AML by 90% (Fig. 1C).